Transvaginal Mesh Settlement from Covidien

CTransvaginal meshovidien, a subsidiary of Medtronic, has announced a transvaginal mesh settlement in some of the cases against it. Approximately 11,300 cases in the transvaginal mesh multidistrict litigations (MDL) implicate Covidien products. While Covidien itself is not the primary defendant in any transvaginal mesh case in the Southern District of West Virginia, Covidien sold transvaginal mesh products to other companies, such as C.R. Bard, who is a party in one MDL. Covidien is indemnifying the manufacturers who sold Covidien products.

More than 100,000 transvaginal mesh lawsuits have been filed in the United States in recent years, including over 70,000 in the Southern District of West Virginia. In settling the suits against them, Covidien joins Endo subsidiary American Medical Systems, who settled the cases against it for $830 million, and Coloplast Corp., who settled its lawsuits for $16 million.

While the number of settled cases against Covidien and the value of the settlements have not been released, Covidien set aside $180 million in the third quarter of 2014 for mesh-related litigation.

Transvaginal Mesh Lawsuits

Plaintiffs’ attorneys in transvaginal mesh lawsuits allege that polyethylene mesh, used to treat stress urinary incontinence and pelvic organ prolapse in women, is unsafe. The mesh can cut into adjacent organs, causing chronic pain and a number of other complications, and frequently requires multiple revision surgeries to fix. Though known to be dangerous and subject to FDA warnings, many transvaginal mesh products are still on the market.

Read more about transvaginal mesh lawsuits here